8-K: Klotho Neurosciences Reprices Warrants to $1.35 and Corrects Private Placement Share Count

Klotho Neurosciences, Inc. has announced a temporary repricing of its public warrants to $1.35 to encourage exercise, alongside a correction to a previously reported $500,000 private placement, now stating 6,250,000 shares were sold.

Summary

• Klotho Neurosciences, Inc. (KLTO) has amended its April 2022 Public Warrants, temporarily reducing the exercise price from $3.49 to $1.35.
• This repriced exercise window is effective from June 10, 2025, at 9:30 AM ET until June 20, 2025, at 4:00 PM ET.
• After June 20, 2025, the exercise price for unexercised public warrants will revert to $3.49.
• The company corrected a previous report regarding a June 5, 2025, stock purchase agreement, clarifying that 6,250,000 shares of common stock were sold for a total purchase price of $500,000, implying a price of $0.08 per share.
• The sale of these shares was made under the exemption from registration provided by Section 4(2) of the Securities Act of 1933, with the purchaser acquiring for investment purposes and deemed capable of evaluating the risks.
• No underwriters or sales commissions were involved in the private placement.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the significant repricing of warrants (implying a low stock price) and the extremely low valuation of the recent private placement ($0.08 per share), both of which suggest severe financial distress and substantial dilution for existing shareholders.

Positives

• The temporary repricing of warrants to $1.35 offers an opportunity for warrant holders to exercise at a significantly reduced cost, potentially increasing the company's cash reserves if warrants are exercised.
• The successful completion of a $500,000 private placement provides additional capital to the company.

Negatives

• The repricing of warrants from $3.49 to $1.35 suggests that the company's stock price is currently trading significantly below the previous exercise price, indicating poor market performance.
• The private placement of 6,250,000 shares for $500,000 implies a per-share price of $0.08, which is substantially lower than both the original and repriced warrant exercise prices, indicating a very low current valuation and significant dilution for existing shareholders.
• The need to correct a previously misstated number of shares in a significant capital raise (Item 3.02) could raise concerns about reporting accuracy.

Risks

• Significant dilution risk for existing shareholders from the exercise of repriced warrants and the recently completed private placement at a very low share price.
• If the stock price does not recover, warrant holders may still choose not to exercise, limiting the capital raised from warrants.
• The low valuation implied by the private placement ($0.08 per share) suggests ongoing financial challenges or a lack of investor confidence.
• The company's ability to meet its operational goals may be constrained by its low valuation and the need for capital at such low prices.

Future Outlook

The company aims to encourage the exercise of public warrants by temporarily reducing their exercise price, which could provide additional capital. The recent private placement also indicates a strategy to secure funding for ongoing operations.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 10, 2025 KLOTHO NEUROSCIENCES, INC. By: /s/ Joseph Sinkule Name: Joseph Sinkule Title: Chief Executive Officer"

Industry Context

The actions taken by Klotho Neurosciences, including warrant repricing and private placements at low valuations, are common strategies for early-stage or struggling biotechnology and neuroscience companies to raise capital when market conditions or company performance make traditional financing difficult. Such moves often reflect a need for immediate liquidity and can be indicative of challenges in drug development or commercialization.

Stakeholder Impact

• **Shareholders:** Face significant dilution from the private placement at a very low price and potential further dilution from warrant exercises. The low valuation implied by these actions negatively impacts their investment.
• **Warrant Holders:** Are presented with a limited-time opportunity to exercise their warrants at a substantially reduced price, potentially making their investment in warrants more viable if they choose to convert.

Next Steps

• Warrant holders have until June 20, 2025, at 4:00 PM ET to exercise their public warrants at the reduced price of $1.35.
• The company will continue its operations, presumably utilizing the capital raised from the private placement and any warrant exercises.

Key Dates

Recommendation

Keywords

Klotho Neurosciences, KLTO, Warrant Repricing, Private Placement, Equity Sale, SEC Filing, 8-K, Common Stock, Capital Raise, Dilution, Neurosciences